Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P L Hudson

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
American Annals of the Deaf|June 1, 1979
Recommitment to the Fitzgerald KeyP L Hudson
Metabolism: Clinical and Experimental|February 1, 1996
Reduction of epidermal growth factor receptor phosphorylation by activated Mullerian inhibiting substance is vanadate-sensitiveM A Maggard, E A Catlin, P L Hudson, et al.
The Journal of Biological Chemistry|January 19, 1996
ICE-LAP3, a novel mammalian homologue of the Caenorhabditis elegans cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosisH Duan, A M Chinnaiyan, P L Hudson, et al.
Cancer Research|March 1, 1992
Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivoR L Parry, T W Chin, J Epstein, et al.
The Journal of Clinical Endocrinology and Metabolism|January 1, 1990
An immunoassay to detect human müllerian inhibiting substance in males and females during normal developmentP L Hudson, I Dougas, P K Donahoe, et al.
The American Review of Respiratory Disease|February 1, 1990
Sex-specific fetal lung development and müllerian inhibiting substanceE A Catlin, S M Powell, T F Manganaro, et al.
The Journal of Biological Chemistry|August 26, 1994
Modulation by sphingolipids of calcium signals evoked by epidermal growth factorP L Hudson, W A Pedersen, W S Saltsman, et al.
Palliative Medicine|November 16, 2022
Strategies and checklist for designing and conducting palliative care research with family carers: EAPC international expert elicitation studyP L Hudson, C Gardiner, A Alvariza, et al.
Endocrinology|July 1, 1992
Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domainD T MacLaughlin, P L Hudson, A L Graciano, et al.
Endocrinology|January 1, 1996
Developmental expression of a candidate müllerian inhibiting substance type II receptorJ Teixeira, W W He, P C Shah, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
American Annals of the Deaf|June 1, 1979
Recommitment to the Fitzgerald KeyP L Hudson
Metabolism: Clinical and Experimental|February 1, 1996
Reduction of epidermal growth factor receptor phosphorylation by activated Mullerian inhibiting substance is vanadate-sensitiveM A Maggard, E A Catlin, P L Hudson, et al.
The Journal of Biological Chemistry|January 19, 1996
ICE-LAP3, a novel mammalian homologue of the Caenorhabditis elegans cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosisH Duan, A M Chinnaiyan, P L Hudson, et al.
Cancer Research|March 1, 1992
Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivoR L Parry, T W Chin, J Epstein, et al.
The Journal of Clinical Endocrinology and Metabolism|January 1, 1990
An immunoassay to detect human müllerian inhibiting substance in males and females during normal developmentP L Hudson, I Dougas, P K Donahoe, et al.
The American Review of Respiratory Disease|February 1, 1990
Sex-specific fetal lung development and müllerian inhibiting substanceE A Catlin, S M Powell, T F Manganaro, et al.
The Journal of Biological Chemistry|August 26, 1994
Modulation by sphingolipids of calcium signals evoked by epidermal growth factorP L Hudson, W A Pedersen, W S Saltsman, et al.
Palliative Medicine|November 16, 2022
Strategies and checklist for designing and conducting palliative care research with family carers: EAPC international expert elicitation studyP L Hudson, C Gardiner, A Alvariza, et al.
Endocrinology|July 1, 1992
Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domainD T MacLaughlin, P L Hudson, A L Graciano, et al.
Endocrinology|January 1, 1996
Developmental expression of a candidate müllerian inhibiting substance type II receptorJ Teixeira, W W He, P C Shah, et al.
Pageof 1